The EEF1E1 Knockout A2780 Polyclonal Cells product comprises a mixed population of A2780 ovarian carcinoma epithelial cells harboring CRISPR/Cas9-mediated disruptions in the EEF1E1 gene. This polyclonal knockout model bypasses the limitations of single-cell clones, offering a broadly representative system to investigate the roles of the translation elongation factor EEF1E1 in epithelial ovarian cancer. The heterogeneous editing events within the population provide a robust loss-of-function platform for functional genomics and drug discovery studies.
The A2780 cell line originates from an untreated human ovarian adenocarcinoma and is a cornerstone model for epithelial ovarian cancer research. These adherent epithelial cells sustain active oncogenic signaling networks and are frequently utilized to examine tumor cell proliferation, apoptosis, DNA repair, and drug resistance. Their sensitivity to chemotherapeutic agents such as cisplatin makes them ideal for mechanistic and translational studies.
EEF1E1 encodes the ?? subunit of the eEF1 complex, which mediates the delivery of aminoacylated tRNAs to elongating ribosomes during protein synthesis. This subunit directly interacts with scaffold proteins AIMP1/p43 and EEF1G, as well as elongation factor EEF1A, to maintain translation fidelity. Upstream, growth factor signaling via mTORC1 phosphorylates translational regulators to coordinate EEF1E1 activity with cellular nutrient status. Downstream, EEF1E1 function impacts global protein synthesis, apoptosis through CASP3 and BCL2, and DNA damage repair via ATM and ATR kinases, thus integrating translation with cell fate decisions.
In the context of A2780 ovarian cancer cells, ablation of EEF1E1 disrupts the delicate balance of translation elongation, leading to attenuated synthesis of proteins essential for sustained proliferation and survival. The resulting proteotoxic stress and impaired DNA damage signaling likely render cells susceptible to apoptosis, driven by altered ratios of BCL2 family members and activation of CASP3. Consequently, this polyclonal knockout model can uncover synthetic lethal relationships and inform strategies to sensitize ovarian tumors to existing therapies.
Researchers can apply this knockout cell population in a variety of assays: Western blotting and RT-qPCR confirm EEF1E1 disruption and downstream effector changes; cell viability, apoptosis, and clonogenic assays evaluate growth and death phenotypes; puromycin incorporation assays measure translation elongation rates; co-immunoprecipitation identifies interacting partners such as AIMP1/p43 or ATM; and drug sensitivity testing assesses chemosensitivity. For further details or assistance, please contact Ascent Research.
